|
|
Cardiovascular Exchange Summit 2011
|
|
|
|
Association of hypertension with absolute and relative risk of stroke and MI
|
|
|
|
Benefits of antihypertensive treatment is proportional to reduction in blood pressure
|
|
|
|
Benefits of antihypertensive treatment is proportional to reduction in blood pressure
|
|
|
|
Deciles of Blood Pressure
|
|
|
|
Deciles of Blood Pressure Variability
|
|
|
|
Patients with episodic hypertension have a high risk of stroke
|
|
|
|
Dia 8
|
|
|
|
ACE-I or ARB beneficial in normotensive atherosclerotic patients
|
|
|
|
Care pathway
|
|
|
|
Care pathway
|
|
|
|
Care pathway
|
|
|
|
Genetic variants in novel pathways influence blood pressure and cardiovascular disease
|
|
|
|
Normal Pressure
|
|
|
|
High Pressure due to Constriction
|
|
|
|
High PressureDue to Increased Volume
|
|
|
|
Evidence for two types of hypertension and response to drugs
|
|
|
|
Comparison of four classes of antihypertensive treatments
|
|
|
|
Correlations between drug pairs
|
|
|
|
Two types of hypertension:Type 1 (high-renin, vasoconstrictor)
|
|
|
|
Two types of drugs for hypertension:Type 1(‘AB’ drugs)
|
|
|
|
Two types of drugs for hypertension:Type 1(‘AB’ drugs)
|
|
|
|
Two types of hypertension:Type 2 (low-renin, Na+ dependent)
|
|
|
|
Two types of hypertension:Type 2 (low-renin, Na+ dependent)
|
|
|
|
Two types of drugs for hypertension:Type 2 (‘CD’ drugs)
|
|
|
|
AB/CD Rule for optimisation of antihypertensive treatment
|
|
|
|
|
Rationale for study
|
|
|
|
Effect of Dose and Combination of Antihypertensives on Interindividual Blood Pressure Variability
|
|
|
|
Rationale for study
|
|
|
|
Rationale for study
|
|
|
|
Rationale for study
|
|
|
|
|
Cambridge ‘abD’ guideline
|
|
|
|
Spironolactone as 4th line treatment in ASCOT
|
|
|
|
Slaying medical myths: Low-dose thiazides are not maximal
|
|
|
|
Double-blind, dose-ranging crossover comparison of diuretics in low-renin hypertension
|
|
|
|
Crossover comparison of glucose tolerance on amiloride and HCTZ
|
|
|
|
The choice of diuretic in hypertension
|
|
|
|
Summary
|
|
Deel deze pagina met collega's en vrienden: